Proteotype Diagnostics

Executive Summary

Proteotype Diagnostics is a UK-based company pioneering a liquid biopsy platform that analyzes the proteotype—the dynamic protein expression profile—to detect, predict, and monitor disease. Unlike traditional diagnostics that rely on signals scaling with disease burden, Proteotype’s approach profiles the host immune response as a leading indicator, enabling earlier detection and real-time monitoring of treatment response and acquired resistance. Founded in 2016 and headquartered in Cambridge, the company focuses on predicting therapeutic outcomes and tracking on-treatment dynamics, positioning its technology as a tool for precision medicine in oncology and potentially other immune-mediated conditions. While still in the private stage with limited public funding details, Proteotype’s novel focus on the proteome could address critical gaps in monitoring drug resistance and immunotherapy response, areas where existing biomarkers often fall short.

Upcoming Catalysts (preview)

• Q4 2026Publication of first clinical validation data in cancer immunotherapy monitoring60% success
• Q1 2027Strategic partnership with a major pharmaceutical company for companion diagnostic development40% success
• TBDCE marking or regulatory submission for lead diagnostic test30% success